文献速递肥胖与代谢综合征

HIV治疗启动后的体重增加:病理生理学与意义

Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

本文综述了HIV抗逆转录病毒治疗(ART)启动后体重增加和肥胖的病理生理学与意义,探讨了该现象近期才被认识的原因、可能机制、对血脂/糖代谢/炎症标志物的影响,以及干预选择(换药、减重策略、抗肥胖药物)。

要点

  • ART启动后体重增加在黑人、女性及治疗时已存在晚期免疫缺陷者中尤为突出。
  • 体重增加机制从早期认为的「恢复健康」扩展到新方案与既往毒性药物的比较效应及药物对线粒体功能的直接影响。
  • 干预选择包括换用ART方案或方案内特定药物、减重策略及抗肥胖药物,但后者尚未在该人群中评估。

核心结论

  • ART启动后体重增加和肥胖已成为许多HIV感染者面临的新困境,尤其在黑人、女性和治疗时已存在晚期免疫缺陷者中。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 体重增加在黑人、女性及开始治疗时已存在晚期免疫缺陷者中尤为突出。
  • 体重增加原因从最初认为的恢复健康,扩展到新方案与既往毒性药物的比较效应及药物对线粒体功能的直接影响。
  • 体重增加对现代ART的影响包括对血脂、糖代谢和炎症标志物的伴随效应。

临床怎么用

  • 干预选择包括换用ART方案或方案内特定药物、减重策略及抗肥胖药物,但抗肥胖药物尚未在该人群中评估。

局限性

  • 抗肥胖药物尚未在HIV感染者与肥胖人群中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid advances in the potency, safety, and availability of modern HIV antiretroviral therapy (ART) have yielded a near-normal life expectancy for most people living with HIV (PLWH). Ironically, considering the history of HIV/AIDS (initially called "slim disease" because of associated weight loss), the latest dilemma faced by many people starting HIV therapy is weight gain and obesity, particularly Black people, women, and those who commenced treatment with advanced immunodeficiency. We review the pathophysiology and implications of weight gain among PLWH on ART and discuss why this phenomenon was recognized only recently, despite the availability of effective therapy for nearly 30 years. We comprehensively explore the theories of the causes, from initial speculation that weight gain was simply a return to health for people recovering from wasting to comparative effects of newer regimens vs prior toxic agents, to direct effects of agents on mitochondrial function. We then discuss the implications of weight gain on modern ART, particularly concomitant effects on lipids, glucose metabolism, and inflammatory markers. Finally, we discuss intervention options for PLWH and obesity, from the limitations of switching ART regimens or specific agents within regimens, weight-gain mitigation strategies, and potential hope in access to emerging antiobesity agents, which are yet to be evaluated in this population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chandiwana NC, Siedner MJ, Marconi VC, et al. Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications. J Clin Endocrinol Metab. 2024. PMID: 37437159. doi:10.1210/clinem/dgad411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。